Efficacy and safety of tiotropium + olodaterol maintenance treatment in patients with COPD in the TONADO® and OTEMTO® studies: a subgroup analysis by age

by Ferguson GT, Karpel JP, Clerisme-Beaty E, Grönke L, Voß F, Buhl R
Published 2016-10-01

Effects of baseline symptom burden on treatment response in COPD

by Martinez FJ, Abrahams RA, Ferguson GT, Bjermer L, Grönke L, Voß F, Singh D
Published 2019-01-01

The lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler®...

by Beeh KM, Derom E, Echave-Sustaeta J, Grönke L, Hamilton A, Zhai D, Bjermer L
Published 2016-02-01